Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : NeoPhore
Deal Size : Undisclosed
Deal Type : Collaboration
NeoPhore Signs Research Collaboration with The Institute of Cancer Research, London
Details : The collaboration will use NeoPhore's proprietary small molecule inhibitors of DNA mismatch repair to investigate single agent activity against tumours with defined genetic backgrounds.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 18, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : NeoPhore
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Recipient : Apollo Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
ICR Announces New Strategic Collaboration With Apollo Therapeutics To Develop Novel Cancer Drugs
Details : Apollo Therapeutics is advancing a pipeline of therapeutic programmes based on breakthrough discoveries. The company identifies and develops pre-clinical and clinical stage assets with strong biological hypotheses and the potential to become meaningful n...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 28, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Recipient : Apollo Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Recipient : Apollo Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration combines the strengths and resources of both organisations to bring forward the development of novel therapies for cancer patients worldwide.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 14, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Recipient : Apollo Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : NXP800
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Nuvectis Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NXP800 is an oral small molecule inhibitor of the Heat Shock Factor 1 (HSF1) pathway, that plays an important role in the initiation and progression of many cancers, is currently in a Phase 1 clinical study.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 03, 2022
Lead Product(s) : NXP800
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Nuvectis Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Avutometinib,Defactinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Drug Combination Shows Promise in Treatment-Resistant Advanced Ovarian Cancer
Details : The treatment combination comprised VS-6766 and defactinib, which can potentially hinder signals ovarian cancer to grow. VS-6766 is a dual RAF/MEK inhibitor of Verastem Oncology while defactinib is a FAK inhibitor.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 19, 2021
Lead Product(s) : Avutometinib,Defactinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Daratumumab
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New Type of Treatment Could Reawaken Immune Response Against Prostate Cancer
Details : Study suggests that therapies which target CD38-such as the multiple myeloma drug daratumumab-could hold promise against prostate cancer too, by reawakening the anti-cancer immune response.
Product Name : Darzalex
Product Type : Antibody
Upfront Cash : Inapplicable
July 05, 2021
Lead Product(s) : Daratumumab
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olaparib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Trial shows Benefits of Targeted Drug Against Early-Stage Breast Cancer with Inherited BRCA Mutation
Details : The OlympiA trial showed that adding olaparib for one year following standard treatment for patients who had an inherited BRCA mutation and early-stage, HER-2 negative breast cancer, cut the risk of their breast cancer returning by 42 per cent at a media...
Product Name : Lynparza
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 06, 2021
Lead Product(s) : Olaparib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EP0042
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Ellipses Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Resistance-Busting ICR Drug Enters Clinical Trial
Details : Ellipses Pharma has rapidly progressed the development of EP0042 following successful negotiations between the ICR and the company, which were led by our Business and Innovation Office.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 19, 2021
Lead Product(s) : EP0042
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Ellipses Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BAY1895344
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 showed promise in patients with a range of advanced, heavily pre-treated cancers, including breast, bowel, and prostate tumors in a dose-escalation portion of a first-in-human phase 1...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 28, 2020
Lead Product(s) : BAY1895344
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olaparib,Capivasertib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : First trial to use the pioneering genetically targeted drug olaparib - already licensed for ovarian, breast and prostate cancer - together with a promising new medicine, called capivasertib.
Product Name : Lynparza
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 14, 2020
Lead Product(s) : Olaparib,Capivasertib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable